Date: 2015-05-28
Type of information: Nomination
Compound:
Company: Juno Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 28, 2015, Juno Therapeutics announced the appointment of Hyam I. Levitsky, M.D., as executive vice president, research and chief scientific officer, effective immediately. Prior to joining Juno, Dr. Levitsky was at Roche, where he was head of cancer immunology experimental medicine. While at Roche, in the Pharma Research and Early Development organization, Dr. Levitsky was responsible for guiding research and early development programs focused on the immunotherapy of cancer, overseeing experimental medicine studies and projects in collaboration with internal and external partners. He also was involved in the selection and validation of targets, the selection of clinical candidates and the establishment of alliances and partnerships with leading research and academic institutions.
During his tenure at Roche, Dr. Levitsky continued to serve as professor of oncology, medicine and urology at The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins Hospital, while maintaining his ongoing research program. His laboratory research focuses on basic studies of antigen processing and presentation, T cell co-stimulation, T cell priming versus tolerance, and the evolution of tumor-specific immunity during immune reconstitution. He is a co-inventor of genetically modified GM-CSF secreting tumor cell vaccines (GVAX). He has been a pioneer in the integration of therapeutic cancer vaccines during immune reconstitution following high-dose chemotherapy and stem cell transplantation. Dr. Levitsky holds five patents.
Dr. Levitsky will report to Mr. Bishop. Mark Frohlich, M.D. will continue to report to Mr. Bishop in his new position as executive vice president, development and portfolio strategy. Ken Mohler, Ph.D., who was serving as chief scientific officer, will become senior vice president, research, working closely with Dr. Levitsky.
Financial terms:
Latest news:
